These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34712948)

  • 41. Overview of the European regulatory approval system.
    Pignatti F; Boone H; Moulon I
    J Ambul Care Manage; 2004; 27(2):89-97. PubMed ID: 15069985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Solving the Global Continual Improvement and Innovation Challenge: How an Effective Pharmaceutical Quality System Can Transform Post-Approval Change Management.
    Vinther A; Ramnarine E
    PDA J Pharm Sci Technol; 2019; 73(5):517-521. PubMed ID: 31420505
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Digital Twins in Biomanufacturing.
    Zobel-Roos S; Schmidt A; Uhlenbrock L; Ditz R; Köster D; Strube J
    Adv Biochem Eng Biotechnol; 2021; 176():181-262. PubMed ID: 33346865
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of current good manufacturing practices and emission regulations and guidances on the discharge of pharmaceutical chemicals into the environment from manufacturing, use, and disposal.
    Velagaleti R; Burns PK; Gill M; Prothro J
    Environ Health Perspect; 2002 Mar; 110(3):213-20. PubMed ID: 11882470
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nanocarriers for intravenous injection--the long hard road to the market.
    Wacker M
    Int J Pharm; 2013 Nov; 457(1):50-62. PubMed ID: 24036012
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
    Senderowicz AM; Pfaff O
    Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU.
    Demirci E; Omes-Smit G; Zwiers A
    Clin Transl Sci; 2023 Jul; 16(7):1127-1133. PubMed ID: 37013379
    [TBL] [Abstract][Full Text] [Related]  

  • 48. UK medicines regulation: responding to current challenges.
    Richards N; Hudson I
    Br J Clin Pharmacol; 2016 Dec; 82(6):1471-1476. PubMed ID: 27580254
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Advancing Product Quality: a Summary of the Inaugural FDA/PQRI Conference.
    Yu LX; Baker J; Berlam SC; Boam A; Brandreth EJ; Buhse L; Cosgrove T; Doleski D; Ensor L; Famulare J; Ganapathy M; Grampp G; Hussong D; Iser R; Johnston G; Kesisoglou F; Khan M; Kozlowski S; Lacana E; Lee SL; Miller S; Miksinski SP; Moore CM; Mullin T; Raju GK; Raw A; Rosencrance S; Rosolowsky M; Stinavage P; Thomas H; Wesdyk R; Windisch J; Vaithiyalingam S
    AAPS J; 2015 Jul; 17(4):1011-8. PubMed ID: 25840884
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Four critical engineering and technical problems in manufacturing measurement of traditional Chinese medicine].
    Wu ZS; Qiao YJ; Xiao W; Wang Q
    Zhongguo Zhong Yao Za Zhi; 2023 Jun; 48(11):2841-2855. PubMed ID: 37381947
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Future of Process Industry: A Cyber-Physical-Social System Perspective.
    Qian F; Tang Y; Yu X
    IEEE Trans Cybern; 2024 Jul; 54(7):3878-3889. PubMed ID: 37607148
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Continuous Manufacturing in Pharmaceutical Process Development and Manufacturing.
    Burcham CL; Florence AJ; Johnson MD
    Annu Rev Chem Biomol Eng; 2018 Jun; 9():253-281. PubMed ID: 29879381
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NIIMBL-Facilitated Active Listening Meeting between Industry and FDA Identifies Common Challenges for Adoption of New Biopharmaceutical Manufacturing Technologies.
    Mantle JL; Lee KH
    PDA J Pharm Sci Technol; 2020; 74(5):497-508. PubMed ID: 32467179
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Intelligent and lean manufacturing for Chinese medicine:theory and its applications].
    Cheng YY; Zhang BL; Fang TH; Liu L; Zhao XP; Ye ZL; Fan XH; Zhang YJ; Li Z
    Zhongguo Zhong Yao Za Zhi; 2019 Dec; 44(23):5017-5021. PubMed ID: 32237332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Provable Data Integrity in the Pharmaceutical Industry Based on Version Control Systems and the Blockchain.
    Steinwandter V; Herwig C
    PDA J Pharm Sci Technol; 2019; 73(4):373-390. PubMed ID: 30770485
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
    Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
    ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Industry One-Voice-of-Quality (1VQ) Solutions: Effective Management of Post-Approval Changes in the Pharmaceutical Quality System (PQS)-through Enhanced Science and Risk-Based Approaches.
    Ramnarine E; Vinther A; Bruhin K; Tovar C; Colao M
    PDA J Pharm Sci Technol; 2020; 74(4):456-467. PubMed ID: 32467177
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.